To date, there is no available tool that allows, at individual level, determination of the probability to develop clinically relevant complications of prolonged glucocorticoid therapy. In patients with inflammatory rheumatic disorders requiring prolonged glucocorticoid therapy, such tool could be useful to adapt first-line treatment decisions (in daily practice and in future clinical trials). The main objective of the study is to identify routine clinical, biological and DXA baseline characteristics predictive of the occurrence of clinically relevant complications of glucocorticoid therapy at 1 year, in order to propose a predictive score.
Study Type
OBSERVATIONAL
Enrollment
300
CHU d'Angers
Angers, France
RECRUITINGCHRU de Brest
Brest, France
RECRUITINGCHD Vendée
La Roche-sur-Yon, France
RECRUITINGCH Le Mans
Le Mans, France
RECRUITINGCH des Pays de Morlaix
Morlaix, France
RECRUITINGCHU de Nantes
Nantes, France
RECRUITINGCHR d'Orléans
Orléans, France
NOT_YET_RECRUITING<CHU de Poitiers
Poitiers, France
RECRUITINGCHIC Quimper
Quimper, France
RECRUITINGClinique St Exupéry
Toulouse, France
RECRUITING...and 1 more locations
Clinically relevant complication of glucocorticoid therapy
The occurrence of one or more clinically relevant complication of glucocorticoid therapy during the first year of treatment, according to the Glucocorticoid Toxicity Index (items and specific list).
Time frame: 1 year
Quality of life assessed through SF-36
Time frame: 1 year
This platform is for informational purposes only and does not constitute medical advice. Always consult a qualified healthcare professional.